Abstract
Objectives
The objective of this study was to combine urine and prostate biopsy rinse material (BRM) assays to increase sensitivity for fusion gene detection.
Patients and methods
A total of 194 patients with suspicion of prostate cancer were prospectively included. Urine samples were collected before or after prostate biopsy, as well as BRM. RT-qPCR was used for the detection of fusion transcripts. A microfocal cancer on biopsy was defined by a single core involved with less than 3 mm of Gleason score 3 + 3 cancer. The association between RT-qPCR and biopsy results was statistically assessed.
Results
Seven patients were excluded because of insufficient material. Cancer was detected on biopsy in 100 (53 %) patients. Urine alone, BRM alone and both samples were obtained in 155, 164 and 132 patients, respectively. In patients with evidence of cancer on biopsy, a fusion transcript was detected in 63, 55 and 73 % of the cases on urine alone, BRM alone and paired samples, respectively. Fusion gene detection on BRM was only associated with the amount of cancer on biopsy. Urine fusion score had a larger area under the curve than serum PSA (p = 0.002) and was significantly higher in patients with high Gleason score and significant cancer on biopsy. Assays of paired samples allowed increasing sensitivity in all subgroups of patients.
Conclusions
TMPRSS2–ERG fusion gene detection may be performed both in the urine and BRM to increase sensitivity. However, only T–E urine score was associated with adverse pathological features.
Similar content being viewed by others
References
Lazzeri M, Abrate A, Lughezzani G et al (2013) Relationship of Chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4–10 ng/mL and normal digital rectal examination. Urology. doi:10.1016/j.urology.2013.10.016
Tombal B, Andriole GL, de la Taille A et al (2013) Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology 81:998–1004
Rubio-Briones J, Fernández-Serra A, Calatrava A et al (2010) Clinical implications of TMPRSS2–ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 183:2054–2061
Perner S, Svensson MA, Hossain RR et al (2010) ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 75:762–767
Tomlins SA, Rhodes DR, Perner S et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648
Liu W, Gong J, Hu J et al (2011) Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score. Urology 77:1006.e1–1006.e7
Lucarelli G, Fanelli M, Larocca AM et al (2012) Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72:1611–1621
Cornu JN, Cancel-Tassin G, Egrot C et al (2013) Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73:242–249
Kirby R, Fitzpatrick JM (2012) Optimising repeat prostate biopsy decisions and procedures. BJU Int 109:1750–1754
Magi-Galluzzi C, Tsusuki T, Elson P et al (2011) TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71:489–497
Wang J, Cai Y, Ren C et al (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347–8351
Soller MJ, Isaksson M, Elfving P et al (2006) Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45:717–719
Clark J, Merson S, Jhavar S et al (2007) Diversity of TMPRSS2–ERG fusion transcripts in the human prostate. Oncogene 26:2667–2673
Mosquera JM, Mehra R, Regan MM et al (2009) Prevalence of TMPRSS2–ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15:4706–4711
Laxman B, Tomlins SA, Mehra R et al (2006) Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8:885–888
Hessels D, Smit FP, Verhaegh GW et al (2007) Detection of TMPRSS2–ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13:5103–5108
Clark JP, Munson KW, Gu JW et al (2008) Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 54:2007–2017
Rostad K, Hellwinkel OJ, Haukaas SA et al (2009) TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 117:575–582
Tomlins SA, Aubin SM, Siddiqui J et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72
Leyten GH, Hessels D, Jannink SA et al (2012) Prospective multicentre evaluation of PCA3 and TMPRSS2–ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. doi:10.1016/j.eururo.2012.11.014
Bories PN, Younes P, Zerbib M et al (2013) TMPRSS2–ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer. Clin Chem 59:245–251
Attard G, Clark J, Ambroisine L et al (2008) Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27:253–263
Barry M, Perner S, Demichelis F et al (2007) TMPRSS2–ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70:630–633
Furusato B, Gao CL, Ravindranath L et al (2008) Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 21:67–75
Demichelis F, Fall K, Perner S et al (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599
Conflict of interest
All the authors declare that they have no conflict of interest.
Ethical standard
All human tissues were obtained in accordance with the ethical policy of the hospital’s Institutional Review Board and methodology was approved by the Ethics Comity of Paris (CPP IdF1-13020). Written consent was obtained from each patient.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delongchamps, N.B., Younes, P., Denjean, L. et al. TMPRSS2–ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material. World J Urol 33, 807–811 (2015). https://doi.org/10.1007/s00345-014-1359-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-014-1359-5